Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 1993Antimicrobial Agents and ChemotherapyOpen Access

In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor

View Full Paper
Ask AI
Bookmark
Share

Authors

MOMichaël OttoNational Institutes of HealthCRCarol ReidMerck & Co., Inc., Rahway, NJ, USA (United States)SGSena GarberDuPont (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Otto et al. (1993) studied this question.

synapsesocial.com/papers/6a9156bdae2c4ed52ef12c60https://doi.org/10.1128/aac.37.12.2606
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An Assay for HIV RNA in Infected Cell Lysates, and its use for the Rapid Evaluation of Antiviral Efficacy1994 · 44 citations
  2. 2Active human immunodeficiency virus protease is required for viral infectivity.1988 · 1,312 citations
  3. 3Structure-based, C2 symmetric inhibitors of HIV protease1990 · 211 citations
  4. 4Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors.1989 · 202 citations
  5. 5Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group1993 · 297 citations